Midatech Pharma Stock Forecast, Price & News

-0.12 (-4.07 %)
(As of 06/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume4.69 million shs
Average Volume1.64 million shs
Market Capitalization$35.87 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MTP News and Ratings via Email

Sign-up to receive the latest news and ratings for Midatech Pharma and its competitors with MarketBeat's FREE daily newsletter.

Midatech Pharma logo

About Midatech Pharma

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.60 out of 5 stars

Medical Sector

1419th out of 2,100 stocks

Pharmaceutical Preparations Industry

631st out of 830 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Midatech Pharma (NASDAQ:MTP) Frequently Asked Questions

What stocks does MarketBeat like better than Midatech Pharma?

Wall Street analysts have given Midatech Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Midatech Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Midatech Pharma's next earnings date?

Midatech Pharma is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Midatech Pharma

How has Midatech Pharma's stock been impacted by COVID-19 (Coronavirus)?

Midatech Pharma's stock was trading at $3.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MTP shares have decreased by 9.3% and is now trading at $2.83.
View which stocks have been most impacted by COVID-19

Who are Midatech Pharma's key executives?

Midatech Pharma's management team includes the following people:
  • Mr. Stephen A. Stamp, CEO, CFO & Director (Age 59, Pay $273.81k)
  • Dr. Steve Damment, Exec. VP of R&D (Age 63, Pay $252.08k)
  • Dr. Tim Sparey Ph.D., Chief Bus. Officer
  • Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP, Head of Manufacturing
  • Mr. David Benharris, Pres of Midatech Pharma US Inc (Age 56)
  • Ms. Fiona Sharp, Group Financial Controller

Who are some of Midatech Pharma's key competitors?

What other stocks do shareholders of Midatech Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Midatech Pharma investors own include CRISPR Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), Vaxart (VXRT), Nabriva Therapeutics (NBRV), Novavax (NVAX), Plug Power (PLUG), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE).

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the NASDAQ under the ticker symbol "MTP."

Who are Midatech Pharma's major shareholders?

Midatech Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Lombard Odier Asset Management USA Corp (3.12%), Renaissance Technologies LLC (2.77%), Citadel Advisors LLC (1.11%), Morgan Stanley (0.73%) and UBS Group AG (0.19%).

Which institutional investors are buying Midatech Pharma stock?

MTP stock was acquired by a variety of institutional investors in the last quarter, including Lombard Odier Asset Management USA Corp, Renaissance Technologies LLC, Citadel Advisors LLC, Morgan Stanley, and UBS Group AG.

How do I buy shares of Midatech Pharma?

Shares of MTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Midatech Pharma's stock price today?

One share of MTP stock can currently be purchased for approximately $2.83.

How much money does Midatech Pharma make?

Midatech Pharma has a market capitalization of $35.87 million and generates $440,000.00 in revenue each year.

How many employees does Midatech Pharma have?

Midatech Pharma employs 18 workers across the globe.

What is Midatech Pharma's official website?

The official website for Midatech Pharma is

Where are Midatech Pharma's headquarters?

Midatech Pharma is headquartered at ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is ODDFELLOWS HOUSE 19 NEWPORT ROAD, CARDIFF X0, CF24 0AA. The company can be reached via phone at 441235888300 or via email at [email protected]

This page was last updated on 6/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.